Incyte Corporation (INCY)
NASDAQ · Healthcare · Biotechnology
Profile
Incyte Corporation
- Exchange
- NASDAQ
- Ticker
- INCY
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Key facts
Incyte Corporation: key facts
- Incyte Corporation (NASDAQ: INCY) is a Biotechnology company in the Healthcare sector.
- In fiscal 2025, Incyte Corporation reported revenue of $5.1B and net income of $1.3B.
- Revenue grew 14.5% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $6.0B and net income was $403.4M.
MonkScore
Incyte Corporation's MonkScore
MonkScore
MonkScore range: 50–60
as of October 2026
Sector rank: 302 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth20–30
- Profitability90–100
- Quality60–70
- Market Conviction30–40
- Safety50–60
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Incyte Corporation's annual figures and the last twelve months, in USD. Last report: 30 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $6.0B | $5.1B | $4.2B | $3.7B | $3.4B | $3.0B |
| Gross profit | $5.6B | $4.8B | $3.9B | $3.4B | $3.2B | $2.8B |
| Operating income | $697.7M | $1.3B | $101.3M | $655.4M | $591.6M | $585.8M |
| Net income | $403.4M | $1.3B | $32.6M | $597.6M | $340.7M | $948.6M |
| Operating cash flow | $745.0M | $1.4B | $335.3M | $496.5M | $969.9M | $749.5M |
| Capital expenditure | -$60.1M | -$58.9M | -$86.3M | -$32.5M | -$77.8M | -$181.0M |
| Free cash flow | $684.9M | $1.4B | $249.1M | $464.0M | $892.1M | $568.5M |
| Total debt | $37.4M | $69.4M | $43.5M | $38.3M | $41.5M | $44.8M |
| Cash | $3.3B | $3.1B | $1.7B | $3.2B | $3.0B | $2.1B |
Revenue growth a year
- 1-year
- 21.2%
- 3-year
- 14.8%
- 4-year
- 14.5%
Compound growth between fiscal years.
Peers
Similar companies
- Vericel CorporationNASDAQ:VCELMonkScore range: 50–60
- Jazz Pharmaceuticals plcNASDAQ:JAZZMonkScore range: 60–70
- Harmony Biosciences Holdings, Inc.NASDAQ:HRMYMonkScore range: 60–70
- Iovance Biotherapeutics, Inc.NASDAQ:IOVAMonkScore range: 60–70
- Nuvation Bio Inc.NYSE:NUVBMonkScore range: 60–70
- MannKind CorporationNASDAQ:MNKDMonkScore range: 60–70
- Theravance Biopharma IncNASDAQ:TBPHMonkScore range: 60–70
- Rhythm Pharmaceuticals, Inc.NASDAQ:RYTMMonkScore range: 60–70
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.